Literature DB >> 31876540

Increased Risk of Acute Myelogenous Leukemia After Early Onset but Not Late-Onset Colorectal Cancer.

Steven Lehrer1, Peter H Rheinstein2.   

Abstract

BACKGROUND: Early onset colorectal cancer in persons younger than 50 years is increasingly common. Clinical and molecular characterizations reveal a distinctive disease. Thirty percent of patients have mutations of hereditary cancer syndromes, especially Lynch syndrome. A recent analysis, testing germline DNA for mutations in 25 cancer susceptibility genes, showed that some patients younger than 50 years had mutations of high-penetrance colorectal cancer genes such as APC (adenopolyposis coli). Others had mutations in high-penetrance or moderate-penetrance genes not traditionally associated with colorectal cancer, such as ATM (ataxia telangiectasia mutated), whereas still others had low penetrance colorectal cancer genes. In the current study, we examined the incidence of second cancers following early onset (age less than 50 y) colorectal cancer.
METHODS: The initial study population was assembled using records from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute. The SEER*Stat MP-SIR (multiple primary-standardized incidence ratio) tool was used to calculate SIRs and excess risk for second primary malignancies. The SIR is expressed as the ratio of observed-to-expected (O/E) cases. We used The Cancer Genome Atlas (TCGA) and AACR Project Genie for genetic analysis. The data were accessed with the online Xena Browser and cBioportal.
RESULTS: Acute myelogenous leukemia (AML) O/E ratios were significantly >1 in patients aged less than 50 years, at 12 to 59 months after colorectal cancer. In patients aged 50 years and older, O/E ratios were equal to 1 or quite close at 12 to 59 months after colorectal cancer. Alterations in 3 AML genes, CEBPA-AS1, MLLT1, and MLLT6, affected the prognosis of colorectal cancer patients less than 50 years but not older than 50 years. One AML gene, FLT3, had the highest copy number alteration frequency of any gene in 1438 colorectal patients 18 to 48 years of age. Genetic alterations of FLT3/TP53 were mutually exclusive. Genetic alterations of FLT3/JAK2 and JAK2/CTNNB1 were co-occurrent.
CONCLUSION: These observations suggest that early onset colorectal cancer and AML may be related diseases.

Entities:  

Mesh:

Year:  2020        PMID: 31876540      PMCID: PMC7103506          DOI: 10.1097/COC.0000000000000658

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.787


  24 in total

1.  Clinical and molecular characterization of early-onset colorectal cancer.

Authors:  Alexandra N Willauer; Yusha Liu; Allan A L Pereira; Michael Lam; Jeffrey S Morris; Kanwal P S Raghav; Van K Morris; David Menter; Russell Broaddus; Funda Meric-Bernstam; Andrea Hayes-Jordan; Winston Huh; Michael J Overman; Scott Kopetz; Jonathan M Loree
Journal:  Cancer       Date:  2019-03-11       Impact factor: 6.860

2.  Rising Proportion of Young Individuals With Rectal and Colon Cancer.

Authors:  Pashtoon Murtaza Kasi; Faisal Shahjehan; Jordan J Cochuyt; Zhuo Li; Dorin Toma Colibaseanu; Amit Merchea
Journal:  Clin Colorectal Cancer       Date:  2018-10-17       Impact factor: 4.481

3.  Three-way translocation involving MLL, MLLT1, and a novel third partner, NRXN1, in a patient with acute lymphoblastic leukemia and t(2;19;11) (p12;p13.3;q23).

Authors:  Sang-Guk Lee; Tae Sung Park; Sung Chul Won; Jaewoo Song; Kyung-A Lee; Jong Rak Choi; Rolf Marschalek; Claus Meyer
Journal:  Cancer Genet Cytogenet       Date:  2010-02

4.  FLT3 and JAK2 Mutations in Acute Myeloid Leukemia Promote Interchromosomal Homologous Recombination and the Potential for Copy Neutral Loss of Heterozygosity.

Authors:  Terry J Gaymes; Azim Mohamedali; Anthony L Eiliazadeh; David Darling; Ghulam J Mufti
Journal:  Cancer Res       Date:  2017-01-20       Impact factor: 12.701

5.  The risk of subsequent primary cancers after colorectal cancer in southeast England.

Authors:  H S Evans; H Møller; D Robinson; C M Lewis; C M J Bell; S V Hodgson
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 6.  Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.

Authors:  Richard M Stone; Paul W Manley; Richard A Larson; Renaud Capdeville
Journal:  Blood Adv       Date:  2018-02-27

Review 7.  Acute myeloid leukemia in the older adults.

Authors:  Antonio M Almeida; Fernando Ramos
Journal:  Leuk Res Rep       Date:  2016-06-16

8.  Emerging treatment options for BRAF-mutant colorectal cancer.

Authors:  Carling Ursem; Chloe E Atreya; Katherine Van Loon
Journal:  Gastrointest Cancer       Date:  2018-03-22

9.  Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients.

Authors:  Takahiko Koyama; Kahn Rhrissorrakrai; Laxmi Parida
Journal:  BMC Cancer       Date:  2019-02-01       Impact factor: 4.430

10.  Investigation of CEBPA and CEBPA-AS Genes Expression in Acute Myeloid Leukemia.

Authors:  Milad Gholami; Sahar Bayat; Saba Manoochehrabadi; Hossein Pashaiefar; Mir Davood Omrani; Hasan Jalaeikhoo; Vahid Reza Yassaee; Mohammad Reza Ebrahimpour; Farkhondeh Behjati; Reza Mirfakhraie
Journal:  Rep Biochem Mol Biol       Date:  2019-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.